Subchronic, reproductive, and maternal toxicity studies with tertiary butyl acetate (TBAC)  by Faber, Willem et al.
Regulatory Toxicology and Pharmacology 68 (2014) 332–342Contents lists available at ScienceDirect
Regulatory Toxicology and Pharmacology
journal homepage: www.elsevier .com/locate /yr tphSubchronic, reproductive, and maternal toxicity studies with tertiary
butyl acetate (TBAC)http://dx.doi.org/10.1016/j.yrtph.2014.01.006
0273-2300  2014 The Authors. Published by Elsevier Inc.
⇑ Corresponding author.
E-mail address: marcy.banton@lyondellbasell.com (M. Banton).
1 The U.S. EPA deﬁnes the cutoff between reactive and negligibly reactive
compounds as being the reactivity of ethane. For compounds with reactivities close
to ethane, the U.S.EPA uses Maximum incremental Reactivities (MIRs) to determine if
a compound is more or less reactive than ethane. The MIR of ethane is 0.26 g O3/g
(SAPRC07). http://www.engr.ucr.edu/~carter/SAPRC/.
2 The MIR of Base ROG Mixture, a mixture representative of all organic gas
atmosphere, is 3.56 g O3/g. Since the cutoff for exempt compounds is 0.2
replacing an average VOC mixture with an exempt mixture will result
reduction in ozone formation.
Open access under CC BY-NC-ND license.Willem Faber a, Daniel Kirkpatrick b, Pragati Coder b, Abby Li c, Susan Borghoff d, Marcy Banton e,⇑
aWFTC, NY, United States
bWIL Research Laboratories, Ashland, OH, United States
cExponent, San Francisco, CA, United States
d Integrated Laboratory Systems, RTP, NC, United States
e LyondellBasell Industries, Houston, TX, United Statesa r t i c l e i n f o
Article history:
Received 9 October 2013
Available online 31 January 2014
Keywords:
Tertiary-butyl acetate
Subchronic
Reproductive
Maternal toxicitya b s t r a c t
Tertiary-butyl acetate (TBAC) was tested for subchronic toxicity in rats and mice and reproductive toxic-
ity in rats at inhalation concentrations of 0, 100, 400 or 1600 ppm. An oral maternal toxicity study was
conducted in rats at dose levels of 0, 400, 800, 1000 and 1600 mg kg1 d1. In the inhalation studies,
hematology, clinical chemistry, urinalysis, gross pathology and the majority of body weight and feed con-
sumption values were unaffected. Exposure to TBAC at concentrations of 400 ppm and higher caused
transient hyperactivity in mice and some evidence of increased motor activity counts in male rats at
the 1600 ppm exposure level. TBAC caused a2u-globulin accumulation in male rat kidneys from all expo-
sure groups and increased liver weights in 1600 ppm rats and mice. Levels of thyroxin were decreased in
male mice exposed to 1600 ppm TBAC for 4 weeks but otherwise thyroid endpoints were unaffected in
rats and mice at either the 4 or 13 weeks time points. There was no evidence or immunotoxicity or repro-
ductive toxicity in rats. Pregnant rats receiving 1000 mg kg1 d1 TBAC exhibited severe signs of acute
neurotoxicity and decreased feed consumption and body weight gain. Fetal viability and growth were
unaffected.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Volatile organic compounds (VOCs) are regulated as tropo-
spheric ozone precursors in the U.S. and Canada. Those volatile or-
ganic compounds that have negligible photochemical reactivity1
can be excluded from the regulatory deﬁnition of a VOC and ex-
empted from VOC emission and product content limits. Thus, substi-
tution of VOC-exempt compounds for photochemically reactive
organic (i.e., VOC) solvents has become an important VOC-compli-
ance strategy. Substitution of exempt compounds for VOCs offers a
number of advantages over other low-VOC technologies, including
lower energy consumption, less retraining of workers, and lowercosts. From an environmental perspective, it is estimated that an
average of 93% reduction in ozone formation from the same emis-
sions can be achieved by replacing a VOC with a VOC-exempt
compound.2
In 1997, tertiary-butyl acetate (TBAC) was developed as a neg-
ligibly reactive solvent, useful in the formulation of coatings, seal-
ants and adhesives, inks, and industrial cleaners. A petition was
submitted to the U.S. Environmental Protection Agency (U.S.EPA)
to have TBAC added to the list of exempt compounds based on
its Maximum Incremental Reactivity (MIR) of 0.17 g/g ozone. In
2004, the U.S.EPA promulgated a ﬁnal rule revising the deﬁnition
of VOCs for the purposes of Federal regulations related to attaining
the National Ambient Air Quality Standards for ozone under Title 1
of the Clean Air Act to exclude TBAC (Code of Federal Regulations,
title 40, Sec. 51.100).es in the
6 g O3/g,
in a 93%
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estimated reduction of 400+ million pounds of ground-level ozone
being formed from solvent emissions in the U.S. and Canada.3 Addi-
tionally, TBAC does not form respirable particulates,4 does not de-
plete stratospheric ozone or contribute to global warming,5 and
does not persist in the environment or bio-accumulate.6 It is also
not a listed carcinogen or reproductive toxicant by the U.S.EPA. How-
ever, at the time of the exemption, developmental, subchronic and
chronic data on TBAC did not exist.
One outcome of the U.S.EPA VOC exemption process was for the
manufacturer to conduct 13-week subchronic TBAC inhalation tox-
icity studies with mice and rats and a reproductive screening study
with rats. Protocols were developed to meet these requirements
that were enhanced with additional endpoints beyond those in-
cluded in the U.S.EPA Test Guidelines 870.3465, 870.3650,
870.6200, and 870.7800.
At the time of these regulatory activities, a paper was published
describing a TBAC developmental toxicity study using the oral
route of exposure (Yang et al., 2007). Since the toxicity of TBAC, fol-
lowing repeated oral exposures, was poorly understood, a study
was designed to investigate maternal toxicity of TBAC following
oral administration as conducted in Yang et al. (2007) and to in-
clude a limit dose (1000 mg kg1 d1) as required in U.S.EPA test
guidelines.
A previous publication (Cruzan and Kirkpatrick, 2006) described
many of the previously conducted studies with TBAC, including
metabolism, acute toxicity and 14-day repeated exposure inhala-
tion toxicity studies. Budroe et al. (2004; Corrigendum, 2006) fo-
cused on acute toxicity values and a cancer risk assessment
based on genotoxicity and cancer bioassays with a metabolite of
TBAC, tertiary butyl alcohol (TBA). The lack of repeated-exposure
studies for TBAC was noted in the Budroe et al. (2004) publication.
The purpose of this publication is to report the ﬁndings of the new
TBAC toxicity studies.2. Methods
2.1. Good laboratory practices
All studies were conducted according to U.S. EPA Good Labora-
tory Practices and OECD Guidelines C (97) 186/Final.
2.2. Test material
Tertiary-butyl acetate (CAS #540-88-5) was provided by Lyon-
dell Chemical Company (Houston, TX, USA) and all batches used
were >98.7% pure.
2.3. Animals and husbandry
Mice (Crl:CD1(IGR)) and rats (Crl:CD(SD)) were received in good
health from Charles River Laboratories, Inc. (Raleigh, NC, USA). Ani-
mals were maintained in accordance with the Guide for the Care
and Use of Laboratory Animals (National Research Council, 1996)
and the animal care programs and facilities of the performing lab-
oratory are fully accredited by the Association for Assessment and3 Based on the difference between the ozone formed from all TBAC used since 2005
(MIR = 0.17 g O3/g) and an equivalent amount of a typical VOC mixture (base ROG
MIR = 3.93 g O3/g).
4 Spyros Spandis, ‘‘Secondary Organic Aerosol Formation Potential for Tert-Buty
Acetate,‘‘ 1998, personal communication.
5 Donald J. Wuebbles, ‘‘Estimated Atmospheric Lifetime and Global Environmenta
Impact from Emissions of Tertiary-Butyl Acetate, ‘‘1998, personal communication.
6 Eva Webster and Don McKay, ‘‘Environmental Fate Analysis of TBAC’’, 1999
personal communication.l
l
,Accreditation of Laboratory Animal Care International (AAALAC
International, Frederick, MD, USA). Animals were acclimatized to
the laboratory for at least 14 days and housed in stainless steel
cages suspended above cage board or in plastic maternity boxes
with ground corncob bedding (Bed-O’Cobs; The Andersons,
Industrial Products Division, Maumee, OH, USA). Animals were
provided with LLC, Certiﬁed Rodent LabDiet 5002 (PMI Nutrition
International, Shoreview, MN, USA) and reverse osmosis-treated
(on-site) drinking water (delivered by an automatic watering sys-
tem) ad libitum except during the inhalation exposure. Animals
were housed in rooms with a controlled average temperature of
21 ± 3 C and an average relative humidity of 50 ± 20%. Fluorescent
lighting provided for a 12 h light/dark photoperiod.
2.4. TBAC vapor generation
TBAC was generated for inhalation exposure as a vapor using a
glass-bead, column-type vaporization system. The test article was
metered to the column, heated to an appropriate temperature to
produce vaporization of the test article and the concentrated va-
pors were piped to the chamber inlet where the concentration
was reduced by mixing with chamber ventilation air. The control
animals were exposed to clean ﬁltered air. Temperature, relative
humidity, chamber ventilation rate and negative pressure within
the exposure chambers were recorded at regular intervals through-
out the 6-hour exposure period (0800–1400 h daily). Actual expo-
sure concentrations were determined by standard gas
chromatographic (GC) methods with sample collection from the
approximate animal-breathing zone of the inhalation exposure
chambers.
2.5. TBAC dosing solutions for maternal oral gavage toxicity study
The TBAC dosing solutions were formulated daily with a corn oil
vehicle and stirred continuously throughout preparation, sampling
and dose administration. All dosing solutions were used within 1–
3 h of preparation.
2.6. Rat subchronic study
Rats (7 weeks of age) were randomized into groups based on
body weight stratiﬁcation in a block design to one of 4 groups con-
taining a total of 10 animals/sex/group. The rats were exposed to 0,
100, 400, or 1600 ppm (0, 473, 1892, 7568 mg m3) TBAC for
6 h d1, 7 days per week for 13 weeks. Clinical examinations were
performed prior to and approximately 1 h following the daily inha-
lation exposure. During exposure, animals that were visible within
the exposure chamber were observed at approximately the
mid-point of the exposure period. The animals were then further
randomized into 4 study replicates for modiﬁed functional obser-
vational battery (FOB) and locomotor activity assessments consistent
with U.S.EPA recommendations (U.S.EPA, 1998). FOB assessments
(Table 1) were recorded for all animals prior to the initiation of
TBAC exposure and before the daily exposure period during weeks
3 and 12. Unlike the clinical examinations, the modiﬁed FOB obser-
vations were conducted by a single observer trained in the conduct
of FOB’s using positive controls, without knowledge of treatment
group. Locomotor activity was assessed following the completion
of the FOB using a photobeam activity system (San Diego Instru-
ments, Inc., San Diego, CA, USA) as described in Chengelis et al.
(2008) and Dmitrienko et al. (2007). Locomotor data was collected
in 5-min epochs and the test session duration was 60 min. Total
and ambulatory motor activity was compiled as four 15-min
subsessions for statistical analysis. Total motor activity was de-
ﬁned as a combination of ﬁne motor skills (repeated interruption
of a single photobeam) and ambulatory motor activity
Table 1
Parameters examined during the Functional Observational Battery (FOB) in rats and
mice (asterisks) during the subchronic inhalation study with TBAC.
Home cage observations
Posture Convulsions/tremors
Feces consistency Biting
Palpebral (eyelid) closure
Handling observations
Ease of removal from cage⁄ Lacrimation/chromodacryorrhea⁄
Piloerection⁄ Palpebral closure⁄
Eye prominence⁄ Red/crusty deposits⁄
Ease of handling animal in hand⁄ Salivation⁄
Fur appearance⁄ Respiratory rate/character⁄
Mucous membranes/eye/skin color⁄ Muscle tone⁄
Open ﬁeld observations (evaluated over a 2 min observation period)
Mobility⁄ Rearing⁄
Convulsions/tremors⁄ Grooming⁄
Bizarre/steareotypic behavior⁄ Time to ﬁrst step (seconds)
Gait⁄ Arousal⁄
Urination/defecation Gait score
Backing⁄
Sensory observations
Approach response Startle response⁄
Pupil response Forelimb extension
Air righting reﬂex⁄ Touch response
Tail pinch response⁄ Eyeblink response
Hindlimb extension Olfactory orientation
Neuromuscular observations
Hindlimb extensor strength Hindlimb foot splay
Grip strength-hind and forelimb⁄ Rotarod performance
Physiological observations
Catalepsy Body temperature⁄
Body weight
Table 2
Tissues and histological features included in an extended immunohistopathology
examination in rats from the subchronic inhalation study with TBAC.
Tissues and histologic features included in extended immunohistopathology
examination
Bone marrow Mediastinal, mandibular, mesenteric and bronchial
lymph nodes
Adipocytes Folliclesa
Cellularity Medullary cordsb
Hematopoiesis,
erythroid
Medullary sinusesc
Hematopoiesis,
myeloid
Paracortexd
Megakaryocytes
Thymus Spleen
Cortex Folliclesa
Apoptosis Interfollicular pulp
Cellularity Erythrocyte rosettes
Cortex-medulla ratio Extramedullary hematopoiesis (EMH)
Epithelial elements Stromal prominence
Tingible body
macrophages
Marginal zone
Medulla Cellularity
Cellularity Size
Epithelial elements Periarteriolar lymphoid sheath (PAL)
Cellularity, Size
a Cellularity, germinal centers and size.
b Cellularity and plasmacytosis.
c Cellularity and histiocytosis.
d Cellularity and high endothelial venules (HEV).
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body weights and feed consumption were recorded weekly start-
ing one week prior to study initiation and continued to study ter-
mination. Ophthalmic examinations were performed on all
animals prior to the initiation of TBAC exposure and during study
week 12. Individual body weights and feed consumption were re-
corded weekly. Final fasted body weights were recorded prior to
scheduled necropsy.
Blood and urine samples for clinical pathology evaluations
(hematology, serum chemistry and urinalysis) were collected from
all animals during study weeks 4 and 13 (scheduled necropsy).
Blood parameters evaluated are listed in the U.S.EPA OPPTS Health
Effects Test Guideline 870.3465 (90-Day Inhalation Toxicity). All
animals were fasted overnight when urine was collected in metab-
olism cages.
A necropsy was performed on all animals following isoﬂurane
anesthesia and exsanguination and included examination of the
external surface, all oriﬁces, and the cranial, thoracic, abdominal
and pelvic cavities, including viscera. Tissues and organs were col-
lected and placed in 10% neutral-buffered formalin as listed in the
U.S.EPA Test Guideline 870.3465. The adrenal glands, brain, epidid-
ymides, kidneys, liver, lungs, ovaries with oviducts, spleen, testes,
thymus, thyroid with parathyroids and uterus were weighed from
all animals at the scheduled necropsy. After routine preparation for
histopathological examination, tissues were examined microscop-
ically. In order to evaluate speciﬁc histological features in greater
detail than what was involved in the initial histological examina-
tion, selected immune system organs were examined a second
time. To facilitate this examination an extendedmicroscopic exam-
ination of the spleen, thymus, Peyer’s patches, bone marrow and
mandibular, mesenteric, bronchial and mediastinal lymph nodes
was conducted (Table 2). Two longitudinal sections of the kidney
from each male rat were subjected to a2u-globulinimmunohistochemical evaluation. In addition, frozen kidney tissue
from each male rat was analyzed for a2u-globulin by ELISA (Borg-
hoff et al., 2009).
2.7. Mouse subchronic study
Mice (7 weeks of age) were randomized into groups based on
body weight stratiﬁcation in a block design of 4 groups containing
a 30 animals/sex/group. The mice were exposed to 0, 100, 400, or
1600 ppm TBAC for 6 h/d, 7 d/week for 13 weeks. Clinical examin-
ations were performed prior to and within 1 hour following the
daily inhalation exposure. These clinical examinations were per-
formed on 30 animals/sex/group during approximately the ﬁrst
4 weeks of the study and on 10 animals/sex/group for the remain-
der of the study. During exposure, animals that were visible within
the exposure chamber were observed at approximately the mid-
point of the exposure period. The during-exposure observations
were difﬁcult to conﬁrm due to their borderline and subjective nat-
ure. When the during-exposure observations were noted in only in
sporadic, inconsistent, isolated incidences during the 13-week per-
iod of daily exposure and observation, they were not considered
test-article related or toxicologically signiﬁcant. FOB observations
(Table 1) were conducted on study days 62 (10 males/group) and
63 (10 females/group) after the end of exposure. Observations
found during the post-exposure clinical examinations were consid-
ered more reliable that the during-exposure ﬁndings due to the
difﬁcult and limitations of observing animals within the exposure
chambers. Ophthalmic examinations were performed on all ani-
mals prior to the initiation of TBAC exposure and during study
week 12. After 10 weeks of inhalation exposure, oestrus cyclicity
was determined for 3 weeks in 10 females per group. Individual
body weights and feed consumption were recorded weekly. Final
fasted body weights were recorded prior to scheduled necropsy.
Terminal blood samples for clinical pathology (hematology and
serum chemistry) were collected from 10 animals/sex/group dur-
ing study week 5. Terminal blood samples were collected from
all surviving animals prior to the scheduled necropsy on study
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are listed in the U.S.EPA OPPTS Health Effects Test Guideline
870.3465. The week 13 necropsy was performed on all animals fol-
lowing isoﬂurane anesthesia and exsanguination and included
examination of the external surface, all oriﬁces, and the cranial,
thoracic, abdominal and pelvic cavities, including viscera. Tissues
and organs were collected and placed in 10% neutral-buffered for-
malin. The adrenal glands, brain, epididymides, kidneys, liver,
lungs, ovaries with oviducts, spleen, testes, thymus, thyroid with
parathyroids and uterus were weighed from all animals at the
scheduled necropsy. After routine preparation for histopatholo-
gical examination, tissues were examined microscopically. In addi-
tion, liver cell proliferation in 10 mice/sex/group was assessed
using immunohistochemical staining for proliferating cell nuclear
antigen (PCNA).
2.8. Reproductive toxicity screening study
Rats (6 weeks of age) were randomized into groups based on
body weight stratiﬁcation in a block design to one of 4 groups con-
taining a total of 10 animals/sex/group. The male and female rats
were exposed individually to 0, 100, 400, or 1600 ppm TBAC for
6 h/d, 7 d/week for 70 days prior to mating, during the mating,
gestation and lactation periods until the day prior to euthanasia
(109–110 days for males and 108–119 days for females). Inhala-
tion exposures of the dams were discontinued after gestation day
20 and resumed on postnatal day 5. The selected F1 offspring were
exposed to the same concentrations of their parents from (post-
weaning) PND 22 through 26. Clinical examinations were
performed prior to and approximately 1 h following the daily inha-
lation exposure. During exposure, animals that were visible within
the exposure chamber were observed at approximately the
mid-point of the exposure period. Individual body weights and
feed consumption were recorded weekly starting one week prior
to study initiation and continued to study termination. Final fasted
body weights were recorded prior to scheduled necropsy. Twenty-
one days prior to pairing, estrous cycles were determined by daily
vaginal lavage and continued until evidence of mating was
observed. Mating pairs were randomly selected within each
exposure group and evidence of mating was conﬁrmed by a vaginal
copulatory plug or sperm positive vaginal lavage (gestation day 0).
Mated females were housed in individual plastic cages with nest-
ing material. F0 female body weights and food consumption were
determined on gestation days 0, 3, 6, 9, 12, 15, 18 and 20 and on
lactation days 1, 4, 7, 14 and 21.
A necropsy was performed on male animals (after the mating
period) and female animals (after selection of the F1 generation)
following isoﬂurane anesthesia and exsanguination and included
examination of the external surface, all oriﬁces, and the cranial,
thoracic, abdominal and pelvic cavities, including viscera. Histopa-
thology of reproductive organs was not conducted since these or-
gans were examined in the subchronic portion of the study.
Immediately upon euthanasia, F0 sperm parameters were collected
as per methods previously described (Faber et al., 2007). Pregnancy
status was determined for females that failed to deliver, and, if
present, the numbers of former implantation sites were
determined.
Beginning on PND 0, pups were sexed and examined for gross
malformations, and the numbers of stillborn and live pups were re-
corded. Each pup was weighed and received a detailed physical
examination on postnatal day (PND) 1, 4, 7, 14 and 21. On PND
4, litters were culled to 10 pups per litter, 5 per sex when possible.
Developmental landmarks recorded for the F1 pups included pinnal
detachment, surface righting response, hair growth, incisor erup-
tion and eye opening. One male and one female F1 pup from each
litter were exposed via inhalation exposure to the sameconcentration of TBAC as their parents for 6 h per day from PND
22-26. F1 pups not selected for inhalation exposure were eutha-
nized on PND 24 and examined internally for gross abnormalities.
F1 pups selected for TBAC exposure were euthanized on PND 27
with a complete necropsy performed.
2.9. Maternal toxicity study
Twelve-week-old nulliparous female rats were bred to resident
males and randomized based on gestation day 0 body weights to
one of 5 groups (22 females/group). Groups were administered
TBAC at dose levels of 0, 400, 800, 1000, 1600 mg kg1 d1 by oral
gavage from gestation day 6 to 20. Corn oil was used as the vehicle
and dosing preparations were prepared daily. Detailed clinical
observations were recorded (prior to dose administration during
the treatment period) from gestation days 0 through 20 and ob-
served for signs of toxicity following dose administration at
approximately 0.25, 0.5, 1 and 2 hours. Individual maternal body
weights and feed consumption were recorded on gestation day 0
and 6–20 (daily).
On gestation day 20, animals were euthanized, exsanguinated
and a laparohysterectomy was performed. The number of corpora
lutea on each ovary was recorded, the uterus was weighed and
opened, and the number and location of all fetuses, early and late
resorptions and the total number of implantation sites were re-
corded. Each viable fetus was individually sexed and weighed.
Adrenal glands, brain, liver, kidneys and thymus from all dams
were weighed with paired organs weighed together. All tissues
were preserved in 10% neutral-buffered formalin. Organ to brain
weight ratios were calculated.
2.10. Statistical analysis
In all studies, statistical analysis was conducted using two-
tailed tests for minimum signiﬁcance levels of 1% and 5%, compar-
ing each test substance-treated group to the control group. Paren-
tal mating, fertility, copulation and conception indices were
analyzed using the Chi-square test with Yates’ correction factor
(Hollander and Wolfe, 1999). Mean body weights, body weight
changes and feed consumption (weekly, gestation and lactation),
clinical pathology, estrous cycle lengths, pre-coital intervals, gesta-
tion lengths, implantation sites, live litter sizes, unaccounted-for
sites, numbers of pups born, F1 developmental landmark data,
absolute and relative organ weights, sperm production rates, epi-
didymal and testicular sperm numbers were analyzed for hetero-
geneity of variance using Levene’s test (Levene, 1960) and for
normality using the Shapiro–Wilk test (Royston, 1982). Continuous
FOB data, the mean maternal body weights, body weight changes,
feed consumption, gravid uterine weights, organ weights and
numbers of corpora lutea, implantation sites and viable fetuses
from the maternal toxicity study were subjected to a parametric
1-way analysis of variance (ANOVA) to determine intergroup
differences (Snedecor and Cochran, 1980). If the ANOVA revealed
statistically signiﬁcant (p < 0.05) intergroup variance, Dunnett’s
test (Dunnett, 1964) was used to compare the test article-exposed
groups to the control group. If the data were not homogeneous and
normally distributed, the Kruskal–Wallis nonparametric ANOVA
test (Kruskal and Wallis, 1952) was used to determine intergroup
differences and if the ANOVA revealed statistically signiﬁcant
(p < 0.05) intergroup variance, Dunn’s test (Dunn, 1964) was used.
Motor Activity was evaluated using the SAS PROC MIXED procedure
for 2-way repeated measure analysis of covariance (RANCOVA)
with dose and intersession time as factors and pretest session as
a covariate. Post-hoc sequential linear trend tests were conducted
on each 15-min intersession time interval after it was determined
that the interaction between dose and intersession time was
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were subjected to a parametric one-way analysis of covariance
(ANCOVA) with live litter size as the covariate, to determine inter-
group differences. If signiﬁcant intergroup differences were de-
tected, a Dunnett’s test (Dunnett, 1964) was used to compare the
test substance-treated groups to the control group.3. Results
3.1. Subchronic studies
In the rat subchronic study, mean inhalation concentrations
were 0, 101.1, 400.3 and 1600.3 ppm (approximately equal to 0,
135, 540 and 2160 mg/kg bw/d). There were no TBAC exposure-re-
lated effects noted during exposure observations, daily clinical
observations, or in the FOB parameters measured on weeks 3 and
12. Post-hoc sequential linear trend analysis with comparison to
the concurrent control group indicated lower locomotor activity
in the ﬁrst 15 min and higher activity in the ﬁnal 15-min interval
in the 1600 ppm males. Higher locomotor activity was present
for the majority of the males in the 1600 ppm group, and the mean
level of activity for the group was higher than the historical control
range of the laboratory. The activity counts during the ﬁrst 0–
15 min interval were comparable to the same time interval during
pretest. With analysis of activity counts from the complete 60-min(a)
(b)
Fig. 1. The effect of TBAC exposure on intersession locomotor activity in rats during
a 13-week subchronic inhalation study. (a) Total (ambulatory and ﬁne) mean male
counts, (b) Female mean total counts. All values are the Mean ± SD of N = 10 rats.session, there were no differences in total (Fig. 1a) locomotor
counts for the TBAC-exposed male groups. There were no effects
on total counts in the female animals for any 15-min interval or
the complete 60-minute session (Fig. 1b). The no-observed-ad-
verse-effect-concentration (NOAEC) for subchronic effects of TBAC
is 400 ppm for motor activity.
During the ﬁrst week of TBAC exposure there was a treatment-
related, transiently lower mean feed consumption (Supplementary
Figure A1) and body weight gain (data not shown) only in the
1600 ppm group male and female rats and that was considered re-
lated to treatment. After the ﬁrst week of exposure, feed consump-
tion and body weight gain in TBAC treated rats was similar to
control animals.
In the subchronic study on mice, mean inhalation concentra-
tions were 0, 101, 400 and 1598 ppm (approximately equal to 0,
237, 948 and 3792 mg/kg bw/d). Evaluations during the inhalation
exposure were limited by the ability to visually inspect only the
animals in the closest to the window of the inhalation chamber
and the inability to conduct a detailed clinical exam. Subjective
ﬁndings of impaired equilibrium and labored respiration were
noted during exposure primarily at the 1600 ppm level, with
inconsistent ﬁndings of impaired equilibrium in two female mice
at 400 ppm. There were only two observations of labored respira-
tion during exposure at 100 ppm level, during exposure, that did
not have a consistent dose response or temporal pattern indicative
of a treatment-related effect. There were also scattered incidences
of hyperactivity and excessive grooming that were not considered
treatment-related because a similar incidence occurred in the con-
trol group or because of a lack of dose–response and temporal pat-
tern (Supplementary Table A1a, A1b). The NOAEC for the during-
exposure ﬁndings was considered to be 400 ppm based upon the
transient clinical ﬁndings in the 1600 ppm group female mice
and equivocal, inconsistent ﬁndings in the 400 ppm group. Acute,
transient observations in mice of hyperactivity, and excessive
grooming were noted during the post-exposure clinical observa-
tions and were considered to be related to TBAC exposure based
on incidence, temporal pattern and appearance of a dose response
relationship (Supplementary Table A1a, A1b). The majority of these
ﬁndings were in the 1600 ppm group animals, with a number of
the 400 ppm group animals being affected every week, although
less consistently than at 1600 ppm. Occurrence of hyperactivity
and excessive grooming was noted occasionally in the 100 ppm
groups, but the temporal pattern was inconsistent and not consid-
ered treatment-related. Impaired equilibrium was also noted in a
few animals (less than 10%) after exposure to 1600 ppm during
the ﬁrst two weeks of exposure. In contrast, no observations were
noted in the modiﬁed FOB assessments that were performed in
mice immediately post-exposure on study days 62 and 63. No
TBAC-related effects were present at the daily pre-exposure obser-
vations. The NOAEC for acute, transient, post-exposure clinical
signs in mice was considered to be 100 ppm based upon the occur-
rence of hyperactivity and excessive grooming noted in the
400 ppm group. There were no effects on body weights and feed
consumption in mice exposed to TBAC (Supplementary Figures
A3a, A3b, and A4).
In rats, TBAC inhalation exposure did not cause any gross le-
sions or altered hematology, clinical chemistry, and urinalysis val-
ues (Supplementary Table A2a, A2b). In the 1600 ppm groups,
there was an increase in liver and/or adrenal weights (absolute
and/or relative to body or brain weights; Table 3). There were no
histopathological ﬁndings related to TBAC exposure in the liver
and adrenal glands in the 1600 ppm groups (Supplementary
Table A3a, A3b). The slightly higher liver and adrenal weights in
male and female rats were within one standard deviation of the
mean values of the historical control for the laboratory.
Table 3
Kidney, liver and adrenal weights in rats from the subchronic inhalation study with TBAC.
Organ Weight Exposure level (ppm) Exposure level (ppm)
Males Females
0 100 400 1600 0 100 400 1600
Kidney
Absolute (g) 3.1 ± 0.12 3.25 ± 0.01 3.37 ± 0.09 3.86 ± 0.01c 1.83 ± 0.06 1.8 ± 0.06 1.98 ± 0.06 2.02 ± 0.07
Relative to body weighta 0.59 ± 0.01 0.65 ± 0.02c 0.68 ± 0.01c 0.77 ± 0.02c 0.654 ± 0.02 0.67 ± 0.02 0.71 ± 0.01 0.74 ± 0.02c
Relative to brain weightb 142.15 ± 5.75 151.85 ± 4.90 160.28 ± 4.00c 181.63 ± 4.44c 93.870 ± 3.29 93.94 ± 3.27 100.01 ± 3.03 104.48 ± 3.27
Liver
Absolute (g) 13.34 ± 0.62 12.83 ± 0.47 12.61 ± 0.52 15.06 ± 0.66 7.50 ± 0.26 7.29 ± 0.21 7.82 ± 0.27 8.71 ± 0.30c
Relative to body weight 2.91 ± 0.10 2.815 ± 0.12 3.045 ± 0.12 3.679 ± 0.13c 2.67 ± 0.06 2.72 ± 0.063 2.809 ± 0.08 3.207 ± 0.07c
Relative to brain weight 612.65 ± 28.93 600.86 ± 25.32 699.81 ± 23.51 707.82 ± 28.57c 383.50 ± 12.46 380.52 ± 12.77 394.57 ± 14.66 450.27 ± 11.90c
Adrenal gland
Absolute (g) 0.063 ± 0.002 0.0601 ± 0.002 0.0640 ± 0.003 0.708 ± 0.002c 0.070 ± 0.003 0.070 ± 0.003 0.072 ± 0.003 0.079 ± 0.003
Relative to body weight 0.012 ± 0.0005 0.012 ± 0.0006 0.013 ± 0.0005 0.016 ± 0.0007c 0.025 ± 0.001 0.026 ± 0.001 0.026 ± 0.001 0.029 ± 0.001
Relative to brain weight 2.550 ± 0.044 2.56 ± 0.046 2.514 ± 0.053 2.98 ± 0.10c 3.57 ± 0.16 3.62 ± 0.17 3.62 ± 0.15 4.11 ± 0.14
All values are the Mean ± SD of N = 10 rats.
a g/100 g terminal body weight.
b g/100 g brain weight.
c Statistically signiﬁcant from control at 0.05.
Table 4
Hormone analysis, TSH, T3 and T4, from study weeks 4 and 13 in rats exposed to TBAC
and thyroid/parathyroid gland weights from study week 13 necropsy.
Control 100 ppm 400 ppm 1600 ppm
Week 4 TSH (ng/mL)
Males 6.6 ± 1.1 8.5 ± 2.6 7.2 ± 2.3 8.0 ± 2.6
Females 6.0 ± 1.0 5.8 ± 0.8 6.2 ± 0.6 6.2 ± 1.4
Week 4 T4 (uG/dL)
Males 7.1 ± 0.9 7.6 ± 1.5 6.5 ± 1.0 6.5 ± 2.3
Females 4.5 ± 1.4 4.3 ± 1.4 4.0 ± 1.1 4.0 ± 0.7
Week 4 T3 (ng/dL)
Males 151.1 ± 25.3 166.8 ± 32.1 153.4 ± 21.3 148.7 ± 31.5
Females 149.6 ± 23.5 140.1 ± 25.3 138.2 ± 18.1 130.5 ± 18.3
Week 13 TSH (ng/mL)
Males 11.3 ± 3.03 13.0 ± 3.36 11.5 ± 2.98 13.0 ± 4.32
Females 11.7 ± 2.0 11.4 ± 2.0 10.4 ± 1.6 11.5 ± 2.3
Week 13 T4 (uG/dL)
Males 5.8 ± 1.3 5.0 ± 0.9 5.3 ± 0.8 4.6 ± 0.8
Females 3.3 ± 0.7 3.8 ± 1.0 3.5 ± 1.3 3.5 ± 0.9
Week 13 T3 (ng/dL)
Males 60.3 ± 11.2 57.5 ± 13.9 50.12 ± 9.5 52.2 ± 14.3
Females 70.4 ± 16.5 77.2 ± 13.6 68.1 ± 12.2 74.0 ± 14.4
Thyroid/parathyroid weights (mg)
Males 23.8 ± 4.3 23.3 ± 3.2 24.6 ± 4.1 26.8 ± 4.4
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brain weights; Table 3) were noted in all TBAC exposed male rats.
Kidney lesions noted upon histological exam were consistent with
a2u-globulin nephropathy and included hyaline droplet (primarily
a2u-globulin) accumulation and basophilic tubules. While a2u-
globulin accumulation (evident by both immunohistopathology
and ELISA analysis) was consistent throughout the TBAC-exposed
groups, tubular basophilia demonstrated a slightly higher inci-
dence and severity in the 1600 ppm exposure group (Fig. 2). De-
spite these alterations, kidney tubular cell proliferation indices
(by PCNA assessment) were similar between TBAC-exposed and
control group animals (Supplementary Table A4). There were no
differences in TSH, total T3 or total T4 in TBAC-exposed rats during
study weeks 4 and 13 (Table 4). Extensive histopathological exam-
ination of lymphoid tissues did not reveal any evidence of immu-
notoxicity in rats exposed to TBAC in the 13-week subchronic
inhalation study.
In mice, TBAC exposure-related changes were limited to in-
creased liver weights (absolute and relative to body and/or brain
weight) in the 1600 ppm male and/or female mice (Table 5) and
a decreased circulating concentration of T4 in male mice (at Study
week 4; Table 6). Histological ﬁndings were limited to centrilobu-
lar hepatocellular hypertrophy in 1/10 female mice from theFig. 2. The effect of TBAC exposure on a-2u-globulin (ng/mg of total protein) in
male rats during a 13-week inhalation study. All values are the Mean ± SD of N = 10
rats.
Females 17.4 ± 2.6 18.6 ± 5.0 17.9 ± 3.1 19.2 ± 5.0
All values are the Mean ± SD of N = 10 rats.1600 ppm group and a very slightly higher PCNA labeling index
in the females at this exposure level. The lower mean T4 levels in
the 1600 ppm male mice group at Study week 4 were not accom-
panied by changes in either mean TSH or T3 levels. There were no
TBAC-related histopathological changes in the thyroid gland at
week 13.
3.2. Reproductive toxicity screening study
The mean inhalation concentrations were 101, 401 and
1604 ppm for the F0 generation and 99.8, 402.7 and 1613.1 ppm
for the F1 generation of the reproductive toxicity phase. There were
no TBAC-related effects on clinical observations, survival, repro-
ductive performance, gross or histopathology, sperm parameters
(Table 7), implantation sites, gestation length or parturition in
any group (Supplementary Table A5). Lower mean weekly body
Table 5
Absolute and relative liver weight and PCNA counts/indices from mice exposed to
TBAC for 13 weeks.
Control 100 ppm 400 ppm 1600 ppm
Liver weight (g)
Males 2.29 ± 0.18 2.12 ± 0.17 2.29 ± 0.17 2.56 ± 0.34
Females 1.50 ± 0.10 1.50 ± 0.21 1.60 ± 0.27 1.84 ± 0.17a
Liver wt./body wt. (% change vs control)
Males 0 3.8 1.7 11.6a
Females 0 0.3 8.1 20.4a
Liver wt./ brain wt. (% change vs control)
Males 0 6.5 6.2 14.2a
Females 0 5.6 4.5 22.8a
PCNA values (#positive nuclei per 2000 cells)
Males 1.4 1.1 2.2 1.6
Females 2.1 1.0 1.4 4.3
PCNA labeling index (%)
Males 0.07 0.06 0.11 0.08
Females 0.11 0.05 0.07 0.22
All values are the Mean ± SD of N = 10 mice.
a Statistically different from the control group at 0.05.
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1600 ppm group F0 male group due to decreased body weight gains
during the ﬁrst 3 weeks of exposure (Fig. 3a). Thereafter there were
no statistically signiﬁcant changes in body weights in male rats or
in female rats during pre-mating, mating, gestation, or lactation
(Fig. 3b). Slightly lower mean feed consumption was observed for
the 1600 ppm group males during the ﬁrst 2 weeks of TBAC expo-
sure with recovery by week 3. There were no effects on feed con-
sumption in the remaining TBAC-exposed male or female F0 rats
(Supplementary Figure A5a, A5b, A5c, A5d).Table 6
TSH, T3, T4 and thyroid/parathyroid gland weights from mice exposed to TBAC for 20 wee
Control 100 ppm
TSH (ng/mL)
Males 0.16 ± 0.028 0.14 ± 0.021
Females 0.08 ± 0.023 0.09 ± 0.030
T4 (uG/dL)
Males 3.64 ± 0.866 3.33 ± 0.845
Females 2.76 ± 0.790 2.34 ± 0.649
T3 (ng/dL)
Males 125.32 ± 19.867 138.55 ± 23.01
Females 123.96 ± 15.620 103.30 ± 19.98
Thyroid/parathyroid weights (mg)
Males 6.2 ± 1.55 5.6 ± 0.92
Females 6.0 ± 0.86 6.2 ± 1.79
All values are the Mean ± SD of N = 9–10 mice.
a Signiﬁcantly different from the control at p < 0.05.
Table 7
Spermatogenesis endpoints in F0 male rats exposed to TBAC.
Control
Mean testicular concentration (millions/g) 53.0 ± 6.2
Mean cauda epid. concentration (millions/g) 579.0 ± 29.28
Sperm production rate (millions/g/d) 9.7 ± 1.0
Motility (%) 99 ± 3.8
Progressive motility (%) 76 ± 5.6
Sperm morphology differential counts (%) 99.9 ± 0.4
Sperm morphology counts (absolute number) 200 ± 0.7
Lt. cauda epid. weight (mg) 322.2 ± 36.8
Lt. testes weight (g) 1.9 ± 0.2
All values are the Mean ± SD of N = 9–10 rats.The mean number of pups born, live litter size, percentage of
males per litter at birth, postnatal survival or development were
unaffected by TBAC exposure (Table 8A and B). No effects were ob-
served on mean body weights or rate of body weight gain in the F1
TBAC-exposed offspring during the lactation period. A slight reduc-
tion in the rate of body weight gain was noted in the F1 female rats
from PND22-23 when exposed to 1600 ppm TBAC. All other F1
groups had no effects on clinical signs, body weights or body
weight gains and were necropsied on PND 27; there were no inter-
nal ﬁndings noted for any F1 animals (Supplementary Table A6).3.3. Maternal toxicity study
TBAC-related clinical observations (rocking, lurching or swaying
while ambulating, walking on tiptoes, splayed hindlimbs, circling
and/or with retropulsion) were noted in a dose- related manner
in the 800, 1000 and 1600 mg kg1 d1 groups within the ﬁrst
2 h following oral dose administration. Additional TBAC-related
clinical observations noted within the ﬁrst 2 h after dose adminis-
tration in the 1600 mg kg1 d1 included hypoactivity, prostration,
impaired use of right and/or left hindlimb, dragging body, and
hunched posture. Lethality due to TBAC administration occurred
in 1 female in the 1600 mg kg1 d1 group and was found dead
47 min following dose administration on gestation day 8 (underly-
ing kidney pathology was present in this animal; see below). All
other animals survived until gestation day 20. Lacrimation and sal-
ivation were noted before and after dose administration in all
TBAC-treated groups throughout the treatment period (data not
shown). Transient decreases in mean feed consumption values
were noted in the 800, 1000 and 1600 mg kg1 d1 groups during
GD 6–9 with concomitant decreases in mean body weight gains
in those same groups during this period (Fig. 4a and b; mean bodyks.
400 ppm 1600 ppm
0.19 ± 0.070 0.17 ± 0.025
0.09 ± 0.033 0.08 ± 0.022
2.83 ± 0.947 2.48 ± 0.520a
2.33 ± 0.718 2.30 ± 0.373
6 133.2 ± 27.611 145.11 ± 16.740
2 121.85 ± 23.871 139.25 ± 18.813
5.5 ± 1.34 5.8 ± 0.91
6.1 ± 1.36 6.5 ± 1.39
100 ppm 400 ppm 1600 ppm
59.8 ± 13.1 60.6 ± 18.0 62.3 ± 11.0
567.4 ± 54.05 530.0 ± 36.65 516.2 ± 36.97
9.8 ± 2.1 9.9 ± 3.0 10.2 ± 1.9
99 ± 4.4 99 ± 6.6 97 ± 4.6
77 ± 6.8 75 ± 6.5 73 ± 5.7
100.0 ± 0.2 99.8 ± 0.4 99.9 ± 0.2
200 ± 0.3 200 ± 0.7 200 ± 0.4
329.0 ± 33.0 334.7 ± 21.0 324.7 ± 26.3
1.8 ± 0.1 2.0 ± 0.5 2.0 ± 0.1
(a)
(b)
Fig. 3. The effects of TBAC exposure on body weight in the F0 generation. (a) Males
were exposed to TBAC for 105 days. (b) Females were exposed to TBAC prior to
pairing, gestation and lactation (approximately 112 days). All values are the
Mean ± SD of N = 10 rats.
Table 8
F1 generation data. (A) The effects of TBAC on mean number of pups born, live litter size, p
postnatal developmental landmarks.
Control
(A)
Number of pups born 14.7 ±
Live litter size 14.6 ±
Sex at birth (% males per litter) 57.2 ±
Postnatal survival on postnatal day 0 99.0 ±
Postnatal survival on postnatal day 0–1 100.0 ±
Postnatal survival on postnatal day 1–4 (pre-selection) 100.0 ±
Postnatal survival on postnatal day 4 (post-selection) to PND 21 100.0 ±
(B)
Pinal detachment (PND 4)
Males 4.0 ±
Females 4.0 ±
Surface righting response (PND 5)
Males 5.2 ±
Females 5.3 ±
Incisor eruption (PND 7)
Males 10.9 ±
Females 10.8 ±
Hair growth (PND 9)
Males 15.6 ±
Females 15.5 ±
Eye opening (PND 13)
Males 15.2 ±
Females 15.1 ±
All values are the Mean ± SD of N = 7–10 litters.
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lower in the 1600 mg kg1 d1 group during the entire treatment
period.
Gross pathology noted in the one 1600 mg kg1 d1 female
found dead on gestation day 8 included a small left kidney with se-
verely distended ureters and a severely dilated renal pelvis. No
TBAC-related internal ﬁndings were noted in any other animal in
any dose group. Increases in absolute mean adrenal weight and
in relative (to brain) mean organ weights were observed in the
adrenal, liver and kidney in the 1600 mg kg1 d1 group (Table 9).
Decreased mean absolute and relative (to brain) thymus weights
were also noted in the 1600 mg/kg bw/d group. No other TBAC-re-
lated effects on absolute organ weights were observed at 400, 800
or 1000 mg kg1 d1.
Mean gravid uterine weights were not affected by TBAC admin-
istration. The mean number of viable fetuses/litter, mean fetal
body weights and historical control values are presented in Table 9.
An unusually low number of live fetuses/litter within the control
group litters was noted along with an increased mean fetal body
weight within those litters. The mean control value of 14.4 fe-
tuses/litter was well below the 25th quartile for the historical con-
trol database value of 14.8 fetuses/litter and well below the
historical control mean of 15.2 fetuses/litter. Coincident with the
decreased number of fetuses/litter in the control group, the mean
fetal body weights in the control group was increased relative to
the TBAC-exposed groups (Table 9). The control mean fetal body
weight value of 3.8 g was well above the 75th quartile for the his-
torical control database value of 3.7 g and well above the historical
control mean of 3.6 g. Similar body weight trends for each sex were
evident with the control mean male and female fetal body weight
values exceeding the 75th quartile for the historical control data-
base values for each sex. The decreases in fetal body weight at
the 400 and 800 mg/kg bw/d groups were not considered test-sub-
stance related due to their being equal to the historical control
mean value of 3.6 g/fetus and the small difference from control
group values (approximately 5%). The larger differences in mean
fetal weight in the 1000 and 1600 mg/kg bw/d groups were consid-
ered test substance related and related to larger litter size andercentage of males per litter at birth and postnatal survival. (B) The effects of TBAC on
100 ppm 400 ppm 1600 ppm
1.8 15.6 ± 2.5 15.4 ± 1.5 13.3 ± 3.7
1.9 15.2 ± 2.6 15.1 ± 1.4 12.6 ± 3.9
4.8 50.3 ± 12.0 49.1 ± 9.9 57.4 ± 12.3
2.7 97.4 ± 3.4 98.3 ± 3.0 94.4 ± 11.7
0.0 98.5 ± 3.2 99.2 ± 2.2 100.0 ± 0.0
0.0 98.1 ± 6.0 100.0 ± 0.0 99.3 ± 2.2
0.0 99.0 ± 6.3 100.0 ± 0.0 100.0 ± 0.0
0.00 4.1 ± 0.32 4.0 ± 0.08 4.0 ± 0.00
0.08 4.0 ± 0.13 4.0 ± 0.00 4.0 ± 0.09
0.17 5.1 ± 0.20 5.3 ± 0.25 5.2 ± 0.34
0.19 5.2 ± 0.23 5.4 ± 0.47 5.2 ± 0.42
0.83 11.1 ± 1.25 10.8 ± 0.94 11.0 ± 0.73
0.60 10.9 ± 1.41 10.6 ± 0.88 10.9 ± 1.07
0.51 15.7 ± 1.65 15.3 ± 1.05 15.4 ± 0.93
0.51 15.6 ± 1.80 15.2 ± 1.15 15.3 ± 1.30
0.63 15.6 ± 1.70 14.7 ± 0.83 15.4 ± 0.61
0.64 15.4 ± 1.78 14.7 ± 0.89 15.2 ± 0.86
(a)
(b)
Fig. 4. The effects of TBAC oral exposure on body weight and feed consumption in
female rats from the maternal toxicity study. (a) Body weight, (b) feed consump-
tion. All values are the Mean ± SD of N = 21–22 rats.
Table 9
The effect of TBAC oral exposure on maternal organ weights and fetal body weights in a m
Control 400 mg/kg bw/d
Absolute organ weight
Brain 1.90 ± 0.016 1.89 ± 0.026
Liver 17.18 ± 0.301 17.38 ± 0.396
Kidneys 2.18 ± 0.038 2.26 ± 0.056
Thymus 0.3033 ± 0.02012 0.2675 ± 0.01505
Adrenal glands 0.0751 ± 0.00224 0.0825 ± 0.00259
Relative to brain weight
Liver 907.54 ± 18.77 923.99 ± 23.73
Kidneys 115.11 ± 2.28 119.98 ± 3.29
Thymus 16.08 ± 1.12 14.19 ± 0.78
Adrenal glands 3.96 ± 0.12 4.38 ± 0.14
Viable fetuses/litter 14.4 ± 0.47 15.5 ± 0.46
fetal body weights 3.8 ± 0.04 3.6 ± 0.07a
Historical control values are 15.2 (±0.05) viable fetuses/litter (25th quartile value of 14.
Mean ± SD of N = 21–22 dams and litters.
a Signiﬁcantly different from the control at 0.05.
b Signiﬁcantly different from the control at 0.01.
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of corpora lutea and implantation sites and the mean litter propor-
tions of preimplantation loss were similar across all groups (Sup-
plementary Table A7).4. Discussion
The thirteen week repeated inhalation exposure studies re-
ported herein demonstrates that TBAC inhalation exposure of up
to 1600 ppm (7568 mgm3) had minimal to no effect on body
weights, feed consumption, hematology, clinical chemistry, urinal-
ysis, and gross pathology. Acute, transient clinical signs of hyperac-
tivity were noted in mice but not in rats. Findings of impaired
equilibrium and labored respiration were noted during exposure
in the 1600 ppm group with equivocal, inconsistent ﬁndings of im-
paired equilibrium noted at 400 ppm (1892 mg m3) in two female
mice during exposure. Clinical observations of hyperactivity,
excessive grooming, impaired equilibrium, and excessive chewing
were noted in mice during the post-exposure observations
throughout the study with lower incidences in the latter part of
the study. The lack of concordance between the during-exposure
clinical signs observed at 400 and 1600 ppm in mice and absence
of post-exposure ﬁndings may be due to differences in testing
methods, or testing at different times of exposure. The NOAEC for
acute, transient, post-exposure clinical signs in mice was consid-
ered to be 100 ppm based upon the occurrence of hyperactivity
and excessive grooming noted in the 400 ppm group during the
post-exposure observation period.
In the rat, there were no effects on the cumulative total and
ambulatory activity for the entire 60-min session. There was a sig-
niﬁcant increase in motor activity counts in the last 15-min period
of the locomotor activity session in the male rats exposed to
1600 ppm TBAC. The remainder of the locomotor activity pattern
in this group was similar to the pre-exposure activity measures.
The NOAEC for subchronic behavioral effects in rats is 400 ppm.
The subjective observation of hyperactivity immediately after
exposure is not consistent with the decreased locomotor activity
more commonly associated with inhalation exposure to acetates
(Bowen and Balster, 1997; Christoph et al., 2003; Cruzan and Kirk-
patrick, 2006). A possible exception is a ﬁnding by Yavich et al.
(1994) that an organic solvent mixture containing 31% ethyl ace-
tate and 25% toluene increased locomotor activity, although tolu-
ene is known to increase activity (Wood and Colotla, 1990;aternal toxicity study.
800 mg/kg bw/d 1000 mg/kg bw/d 1600 mg/kg bw/d
1.89 ± 0.009 1.87 ± 0.048 1.86 ± 0.021
17.53 ± 0.403 17.55 ± 0.333 18.56 ± 0.360
2.29 ± 0057 2.32 ± 0.040 2.34 ± 0.031
0.2759 ± 0.02143 0.2629 ± 0.01544 0.2021 ± 0.01533 b
0.0795 ± 0.00224 0.0809 ± 0.00310 0.0934 ± 0.00264b
928.95 ± 20.64 936.47 ± 15.51 999.65 ± 22.73b
121.31 ± 3.03 123.56 ± 1.86 125.68 ± 1.77a
14.65 ± 1.16 14.03 ± 0.81 10.91 ± 0.87b
4.21 ± 0.12 4.313 ± 0.16 5.02 ± 0.14b
15.2 ± 0.43 15.4 ± 0.37 15.9 ± 0.44
3.6 ± 0.04a 3.5 ± 0.05b 3.4 ± 0.05b
8); mean fetal body weight = 3.6 (±0.10) g (75th quartile = 3.7 g). All values are the
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creased CNS excitability (jumps in air, seizures, wet-dog shakes)
and impaired gait in mice that recovered within minutes of re-
moval from the exposure chamber following exposure to amyl,
ethyl and n-butyl acetate. Thus, the increased incidence of hyper-
activity, impaired equilibrium and excessive grooming observed
in mice in the present TBAC study could be related to CNS excit-
ability. The rapid reversibility of acetate effects reported by Bowen
and Balster (1997) could explain why effects were reported as
clinical observations which were quicker to conduct on all animals
compared to the FOB. Subacute inhalation to TBAC produced no
clinical ﬁndings in mice (190–1500 ppm) and severe clinical ﬁnd-
ings including hypoactivity, rapid shaking of head, impaired
coordination and gait in rats (1500–5066 ppm, NOEL 430 ppm)
(Cruzan and Kirkpatrick, 2006). Thus, the NOAECs for clinical ﬁnd-
ings reported in the present studies are consistent with the
NOAECs reported by Cruzan and Kirkpatrick (2006), although the
types of ﬁndings were different. Increases in cumulative test
session motor activity counts have also been reported in female
F344 rats exposed to 5000 ppm isopropanol for 9 or 13 weeks and
were reversible shortly after cessation of exposure (Burleigh-Flayer
et al., 1998).
Effects on body weight gain and feed consumption were limited
to transient decreases in the 1600 ppm group male and female rats
during the ﬁrst week of exposure with no other body weight effects
being observed in either mice or rats for the remainder of the
study. Adverse effects in rats were limited to changes in the kid-
neys of TBAC-exposed male rats that were consistent with a2u-
globulin nephropathy. A metabolite of TBAC, tertiary butyl alcohol
(TBA) has also been reported to cause an increase in kidney tumors
in F-344 male rats following chronic exposures in drinking water
(Cirvello et al., 1995) and a2u-globulin nephropathy following
inhalation exposure (Borghoff et al., 2001). TBA did not affect the
thyroids of male and female F-344 rats when exposed chronically
via drinking water (Cirvello et al., 1995) and TBAC inhalation expo-
sures in this study did not affect circulating levels of thyroid hor-
mones or thyroid histopathology in rats. Extensive examination
of lymphoid tissues did not reveal any evidence of TBAC causing
immunotoxicity in rats.
Increased liver weights were noted in male and female mice ex-
posed to 1600 ppm TBAC for 13 weeks with limited evidence of
centrilobular hepatocellular hypertrophy in female mice. The
TBAC-related lower circulating T4 levels in the male mice
1600 ppm group following 4 weeks of exposure may be related
to hepatic metabolizing enzyme induction with higher turnover
of T4 since the liver is the primary site of both deiodination of T4
to produce active T3 and inactive reverse-T3 and T2 and enzymatic
conjugation of T4 to glucuronides and sulfates that are excreted
(Farwell and Braverman, 1996). The increased liver weight (with-
out ﬁndings indicative of liver injury) observed in male and female
mice exposed to 1600 ppm are consistent with the presence of
metabolizing enzyme induction. A slightly higher PCNA labeling
index suggests that some of the increase in liver weight in that
group is also due to cell proliferation (Table 5). TBA administered
in the drinking water for 14 days has been demonstrated to induce
phase I and II liver enzymes in female mice (Blanck et al., 2010)
with subsequent effects on thyroid hormone homeostasis. No evi-
dence of thyroid pathology was noted in the Blanck et al. (2010)
study. No TBAC-related histopathological changes to the thyroid
were present in either male or female mice in this study following
13 weeks of inhalation exposure.
The metabolism of TBAC has been reported previously (Cruzan
and Kirkpatrick, 2006). Hydrolysis of the ester bond in TBAC is one
of the two major metabolic pathways, forming TBA. The ester
hydrolysis pathway was favored at the 1000 ppm exposure level.
Information on the toxicokinetic proﬁle of TBAC in rats followinginhalation exposures was reported by Groth and Freundt (1994).
Following inhalation exposure to either 437 or 898 ppm TBAC,
blood levels of TBAC increase during a 5-h inhalation exposure
with lower levels reported after cessation of the inhalation expo-
sure. Blood levels of TBA also increase during the exposure and ex-
ceed blood TBAC levels after approximately 4 h. Following
cessation of the 898 ppm inhalation exposure, the blood levels of
TBAC dropped rapidly while the TBA levels decreased more slowly.
TBAC inhalation exposure did not affect any of the parameters
collected in the rat reproductive toxicity screening study. Sperm
parameters, reproductive performance, postnatal survival and
postnatal development of the offspring were unaffected. A slight
decrease in body weight gain in the F1 female pups when directly
exposed to 1600 ppm TBAC was noted following the ﬁrst day of
exposure. No other adverse effects were noted in weanling rats di-
rectly exposed to up to 1600 ppm TBAC. In contrast, pregnant rats
receiving 800, 1000 or 1600 mg kg1 d1 by oral gavage bolus
doses exhibited severe clinical signs of neurotoxicity and decreases
in feed consumption in these same groups led to decrements in
body weight gain between GD 6 and 9. Gravid uterine weights
and mean number of viable fetuses/litter were unaffected; indeed
the exposed groups had between 0.8 and 1.5 more pups per litter
than the control group. The unusually small litter size in the con-
trol group resulted in greater mean fetal body weights when com-
pared to the fetal body weights from the ‘‘normal sized’’ litters
found in the exposed groups. These results demonstrate the mater-
nal toxicity caused by oral administration of large amounts of TBAC
with a concomitant lack of effect on fetal viability at all dose levels
and fetal body weight at the 400 and 800 mg/kg bw/d dose levels.
Similar adverse effects from oral administration of 1600 mg kg1
d1 exposure, were reported by Yang et al. (2007), although they
did not report any adverse effects in dams receiving 800 mg kg1
d1. In addition, oral TBAC exposure had no effect on live litter size
in the study by Yang and colleagues, conﬁrming our interpretation
of the litter size results observed in this study.
In conclusion, repeated inhalation exposure ofP400 ppm TBAC
for thirteen weeks caused clinical observations of hyperactivity in
mice immediately post-exposure. These reversible clinical signs
could not be conﬁrmed when the mice were examined by a tech-
nician unaware of treatment status conducting a modiﬁed FOB.
An increase in motor activity counts in male rats during the last
15-min of 1-h session following 13 weeks of exposure to
1600 ppm TBAC suggests a slight behavioral response in male rats.
Repeated exposure to TBAC for 13 weeks did not affect body
weight, feed consumption, and immunopathology endpoints. TBAC
caused a2u-globulin accumulation within the male rat kidney. In-
creased liver and adrenal weights in rats were not accompanied by
histopathological changes in those organs. Thyroid endpoints were
not affected in male and female rats while male mice had de-
creased concentrations of T4 at study week 4 but not week 13.
There was no evidence that TBAC caused reproductive toxicity fol-
lowing repeated inhalation exposures throughout premating, mat-
ing, gestation and lactation. Oral gavage dose administration of
TBAC to pregnant rats at dose levels ofP 800 mg/kg/d caused sig-
niﬁcant signs of acute neurotoxicity and transient decreases in feed
consumption and body weight gain in pregnant dams. Limited fetal
evaluations indicated that exposure to maternally toxic dose levels
of TBAC did not affect fetal viability.Conﬂict of interest
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